CN1259948A - 6,7-二取代-4-氨基吡啶并[2,3-d]嘧啶化合物 - Google Patents

6,7-二取代-4-氨基吡啶并[2,3-d]嘧啶化合物 Download PDF

Info

Publication number
CN1259948A
CN1259948A CN98806072A CN98806072A CN1259948A CN 1259948 A CN1259948 A CN 1259948A CN 98806072 A CN98806072 A CN 98806072A CN 98806072 A CN98806072 A CN 98806072A CN 1259948 A CN1259948 A CN 1259948A
Authority
CN
China
Prior art keywords
phenyl
amino
methyl
pyrimidine
pyrido
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN98806072A
Other languages
English (en)
Chinese (zh)
Inventor
S·S·巴格瓦特
李志宏
R·J·佩尔纳
顾禹归
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of CN1259948A publication Critical patent/CN1259948A/zh
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN98806072A 1997-04-16 1998-04-16 6,7-二取代-4-氨基吡啶并[2,3-d]嘧啶化合物 Pending CN1259948A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83439397A 1997-04-16 1997-04-16
US08/834,393 1997-04-16

Publications (1)

Publication Number Publication Date
CN1259948A true CN1259948A (zh) 2000-07-12

Family

ID=25266829

Family Applications (1)

Application Number Title Priority Date Filing Date
CN98806072A Pending CN1259948A (zh) 1997-04-16 1998-04-16 6,7-二取代-4-氨基吡啶并[2,3-d]嘧啶化合物

Country Status (20)

Country Link
EP (1) EP0979230A1 (xx)
JP (1) JP2001520649A (xx)
KR (1) KR20010006453A (xx)
CN (1) CN1259948A (xx)
AR (1) AR012435A1 (xx)
AU (1) AU744528B2 (xx)
BG (1) BG103861A (xx)
BR (1) BR9809088A (xx)
CA (1) CA2287465A1 (xx)
CO (1) CO4940439A1 (xx)
HU (1) HUP0001402A3 (xx)
IL (1) IL131892A0 (xx)
NO (1) NO995033L (xx)
NZ (1) NZ337844A (xx)
PL (1) PL336262A1 (xx)
SK (1) SK142099A3 (xx)
TR (1) TR199902456T2 (xx)
TW (1) TW458977B (xx)
WO (1) WO1998046603A1 (xx)
ZA (1) ZA982912B (xx)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100376571C (zh) * 2001-02-12 2008-03-26 霍夫曼-拉罗奇有限公司 6-取代的吡啶并嘧啶类化合物

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001057040A1 (en) * 2000-02-03 2001-08-09 Abbott Laboratories 6,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
KR20070086076A (ko) 2004-11-12 2007-08-27 트러스티즈 오브 터프츠 칼리지 리파아제 억제제
EP2139332A4 (en) * 2007-03-28 2010-04-21 Merck Sharp & Dohme SUBSTITUTED PYRIDO [2,3-D] PYRIMIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS
BR112015007182A2 (pt) * 2012-10-05 2017-07-04 Rigel Pharmaceuticals Inc inibidores de gdf-8
WO2017205848A1 (en) * 2016-05-27 2017-11-30 Legacy Emanuel Hospital & Health Center Methanocarba derivatives of pseudoribose that inhibit adenosine kinase

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB774094A (en) * 1953-01-02 1957-05-08 Wellcome Found Improvements in or relating to pyrimidine compounds
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100376571C (zh) * 2001-02-12 2008-03-26 霍夫曼-拉罗奇有限公司 6-取代的吡啶并嘧啶类化合物

Also Published As

Publication number Publication date
TW458977B (en) 2001-10-11
KR20010006453A (ko) 2001-01-26
AU744528B2 (en) 2002-02-28
PL336262A1 (en) 2000-06-19
ZA982912B (en) 1998-10-09
BG103861A (en) 2000-06-30
AR012435A1 (es) 2000-10-18
EP0979230A1 (en) 2000-02-16
TR199902456T2 (xx) 2000-07-21
BR9809088A (pt) 2000-08-01
NO995033D0 (no) 1999-10-15
SK142099A3 (en) 2000-05-16
NZ337844A (en) 2001-11-30
CO4940439A1 (es) 2000-07-24
JP2001520649A (ja) 2001-10-30
NO995033L (no) 1999-12-15
HUP0001402A2 (hu) 2000-10-28
IL131892A0 (en) 2001-03-19
CA2287465A1 (en) 1998-10-22
HUP0001402A3 (en) 2001-01-29
AU7098198A (en) 1998-11-11
WO1998046603A1 (en) 1998-10-22

Similar Documents

Publication Publication Date Title
CN100351250C (zh) 对gsk3具有选择性抑制作用的新型化合物
EP1355889B1 (en) Substituted triazole diamine derivatives as kinase inhibitors
TWI519515B (zh) B型肝炎抗病毒劑
EP2296653B1 (en) Compounds and methods for treating inflammatory and fibrotic disorders
CA2939219C (en) Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
KR100667645B1 (ko) 환상 아민 ccr3 길항제
EP2620433B1 (en) Substituted amide compound
JP2008510018A (ja) フルクトース−1,6−ビスホスファターゼの新規チアゾール阻害物質
CN1283192A (zh) 用芳基取代或杂芳基取代的杂环脲抑制raf激酶
JP2000501694A (ja) 複素環置換シクロペンタン化合物
AU2024202745A1 (en) Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
JP2001520655A (ja) 5,7−ジ置換4−アミノピリド[2,3−d]ピリミジン化合物およびアデノシンキナーゼ阻害剤としてのその用途
WO2006071035A1 (en) Novel ([1,3]thiazolo[5,4-b]pyridin-2-yl)-2-carboxamide derivatives
JP2014507453A (ja) 1H−ピロロ[3,2−d]ピリミジンジオン誘導体
JPWO2014133134A1 (ja) 新規テトラヒドロピリドピリミジノン誘導体
CN1259948A (zh) 6,7-二取代-4-氨基吡啶并[2,3-d]嘧啶化合物
KR20210126636A (ko) 이환식 설폰아마이드
EP1908752A1 (en) Novel 2-quinolone derivative
JP2003212846A (ja) 縮合環化合物及びc型肝炎治療剤
US6030969A (en) 5,6,7-trisubstituted-4-aminopyrido[2,3-D] pyrimidine compounds
JP4518587B2 (ja) 2−フェニルモルホリン誘導体
JP2001520654A (ja) 5,6,7−三置換−4−アミノピリド[2,3−d]ピリミジン化合物
CZ360199A3 (cs) Sloučeniny 6,7-disubstituovaného-4- aminopyrido [2,3-dJ pyrimidinu
CZ350899A3 (cs) 5,6,7-trisubstituované-4-aminopyrido-[2,3- D]pyrimidinové sloučeniny
MXPA99009512A (en) 5,6,7-trisubstituted-4-aminopyridol[2,3-d]pyrimidine compounds

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication